Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 10, 2013, authorized by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,453,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,566 pence per share; lowest was 1,536.50 pence per share.
- Treasury Holdings (Settled): 491,572,412 shares (9.16% of total issued share capital).
- Treasury Holdings (Including Unsettled): 495,921,912 shares (10.17% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,874,571,674 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,453,000 shares on October 10, 2013. Consequently, the percentage of shares held in Treasury increased to 9.16% of issued capital and 10.17% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (491,572,412 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights (10.17%) including unsettled shares for disclosure threshold assessments.
- Review the remaining authorization for share buybacks under the mandate granted on May 1, 2013.
- Check the Financial Conduct Authority's Disclosure and Transparency Rules for notification requirements based on the 4,874,571,674 shares in issue.